Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.56 |
| ▸ | CMA1 | P23946 | 4/20 | 0.53 |
| ▸ | REN | P00797 | 1/20 | 0.53 |
| ▸ | CTSD | P07339 | 2/20 | 0.48 |
| ▸ | CTSE | P14091 | 2/20 | 0.48 |
| ▸ | BACE1 | P56817 | 2/20 | 0.48 |
| ▸ | CTSK | P43235 | 7/20 | 0.48 |
| ▸ | CTSL | P07711 | 4/20 | 0.48 |
| ▸ | CTSS | P25774 | 3/20 | 0.48 |
| ▸ | ELANE | P08246 | 1/20 | 0.48 |
| ▸ | CTSB | P07858 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20335531 | 0.94 | MALT1 (0.55) | MALT1CMA1RENCTSDCTSE | |
| SCHEMBL20335530 | 0.94 | MALT1 (0.55) | MALT1CMA1RENCTSDCTSE | |
| SCHEMBL20335533 | 0.94 | MALT1 (0.55) | MALT1CMA1RENCTSDCTSE | |
| SCHEMBL20353398 | 0.94 | MALT1 (0.54) | MALT1CMA1RENCTSDCTSE | |
| SCHEMBL12257217 | 0.92 | MALT1 (0.52) | MALT1CMA1RENCTSDCTSE | |
| SCHEMBL28051124 | 0.91 | CMA1 (0.57) | MALT1CMA1RENCTSKCTSL | |
| SCHEMBL12308843 | 0.90 | MALT1 (0.51) | MALT1CMA1RENCTSDCTSE | |
| SCHEMBL15061604 | 0.90 | MALT1 (0.52) | MALT1CMA1RENCTSDCTSE | |
| SCHEMBL25216227 | 0.89 | MALT1 (0.55) | MALT1CMA1RENCTSDCTSE | |
| SCHEMBL12257215 | 0.87 | MALT1 (0.52) | MALT1CMA1RENCTSDCTSE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3405477-B1 | INHIBITORS OF TRANSGLUTAMINASES | ZEDIRA GMBH (DE) | 2023-06-07 | — | — | EP | disclosed |
| EP-2086993-B1 | MICHAEL SYSTEMS AS TRANSGLUTAMINASE INHIBITORS | ZEDIRA GMBH (DE) | 2015-03-11 | — | — | EP | disclosed |
| US-8471063-B2 | Michael systems as transglutaminase inhibitors | ZEDIRA GMBH (DE) | 2013-06-25 | — | — | US | disclosed |
| US-20110229568-A1 | MICHAEL SYSTEMS AS TRANSGLUTAMINASE INHIBITORS | ZEDIRA GMBH (DE) | 2011-09-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110229568-A1 | MICHAEL SYSTEMS AS TRANSGLUTAMINASE INHIBITORS | TGM2, TGM3, TGM1 | MALT1 385/4885CMA1 114/4885REN 1458/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.